Brief: X4 Pharmaceuticals Granted Fast Track Designation For Mavorixafor For Treatment Of Chronic Neutropenia By US FDA
10/06/2025 13:55
June 10 (Reuters) - X4 Pharmaceuticals Inc XFOR.O: X4 PHARMACEUTICALS GRANTED FAST TRACK DESIGNATION FOR MAVORIXAFOR FOR THE TREATMENT OF CHRONIC NEUTROPENIA BY U.S. FDA X4 PHARMACEUTICALS INC - CONDUCTING PHASE 3 TRIAL FOR MAVORIXAFOR IN CN Source text: ID:nGNX7SlgJY Further company coverage: XFOR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on X4 Pharmaceuticals
See all newsBrief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule